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Abstract
Background Solid tumors are a common predisposing factor for invasive candidiasis (IC) or candidemia due to IC.
Objectives Post hoc analysis of patient-level efficacy and safety data from six studies of anidulafungin (with similar protocols/
endpoints) in adults with IC/candidemia summarized by past or recent diagnosis of solid tumors.
Patients/methods Patients received a single intravenous (IV) dose of anidulafungin 200 mg, followed by 100 mg once daily. 
After ≥ 5 to ≥ 10 days of IV treatment, switch to oral voriconazole/fluconazole was permitted in all but one study. Time 
of solid tumor diagnosis was defined as past, ≥ 6; and recent, < 6 months prior to study entry. Primary endpoint: global 
response of success (GRS) rate at the end of IV therapy (EOIVT). Secondary endpoints included the GRS rate at the end of 
all therapy (EOT), all-cause mortality, and safety.
Results The GRS rate in the overall population was 73.4% at EOIVT and 65.5% at EOT. Past or recent solid tumor diagnosis 
did not affect GRS at EOIVT or EOT (past: 75.5% and 71.4%; recent: 72.2% and 62.2%, respectively). All-cause mortality 
was 14.4% on day 14 and 20.1% at day 28. Most treatment-emergent adverse events were mild/moderate in severity (81.6%).
Conclusions Treatment of IC was effective regardless of the time of solid tumor diagnosis.
Trial Registration Data were pooled from six studies: NCT00496197 (first posted on ClinicalTrials.gov on July 4, 2007); 
NCT00548262 (first posted on ClinicalTrials.gov on October 23, 2007); NCT00537329 (first posted on ClinicalTrials.gov 
on October 1, 2007); NCT00689338 (first posted on ClinicalTrials.gov on June 3, 2008); NCT00806351 (first posted on 
ClinicalTrials.gov on December 10, 2008); NCT00805740 (first posted on ClinicalTrials.gov on December 10, 2008).
Plain Language Summary
Patients with solid tumor cancers (cancer of internal organs) have increased risk of fungal infections that can spread in the body 
through the blood. Infection with Candida species, known as invasive candidiasis (IC) (Candida invades the body in places 
normally free from germs) or candidemia (Candida infection in the blood), can cause severe illness and/or death. Anidulafungin 
is an antifungal drug recommended to treat IC/candidemia. This post hoc analysis looked at how effective and safe anidulafungin 
was in adult patients with IC/candidemia with ‘recent’ or ‘past’ history of solid tumors. The analysis included patients diagnosed 
with cancer less than 6 months before (recent history) or more than 6 months before (past history) they first received anidu-
lafungin. Patients received anidulafungin by injection (intravenously [IV]) into the veins and, for continued treatment, were able 
to take a different antifungal drug orally. Of 539 patients from six studies, 139 had confirmed IC/candidemia and a history of 
solid tumors. Approximately 7 out of 10 (72%) patients were cured or no longer had signs of Candida infection at the end of IV 
anidulafungin treatment. Results were similar in patients with past or recent diagnosis of solid tumors. Treatment side effects 
reported in approximately 8 out of 10 (82%) patients were mild-to-moderate in severity. This analysis suggests anidulafungin was 
well tolerated and effective at treating IC/candidemia in patients with solid tumors, whether diagnosed recently or in the past.
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Key Points 
The primary measure of efficacy used in this study 
(global response of success rate) at the end of IV 
treatment with anidulafungin in patients with invasive 
candidiasis/candidemia and solid tumors was compara-
ble to that of a representative sample of patients with IC/
candidemia.
In this analysis, treatment with anidulafungin was effec-
tive irrespective of a past or recent diagnosis of solid 
tumors.
1 Introduction
Patients with cancer, particularly solid tumors and hemato-
logic malignancies, are at increased risk of invasive candidi-
asis (IC) [1] or candidemia due to IC [2]. In an analysis of 
European multi-institutional surveys of patients with can-
didemia, an underlying pathology of solid tumors was the 
third-most common factor associated with IC/candidemia, 
after surgery and intensive care treatment [3]. Candida 
species are a frequent cause of invasive fungal infection in 
patients with many different types of solid tumors, including 
gastrointestinal, breast, ear/nose/throat, genitourinary, head 
and neck, hematologic, lung, liver, and skin [2, 4–8].
In epidemiology and surveillance studies, morbidity and 
mortality outcomes of IC in patients with solid tumors and 
hematologic cancers were poor [3, 4, 9], with mortality rates 
between 30 and 65% [3–7, 9, 10]. In addition to older age 
and advanced disease, surgery, admission to the intensive 
care unit (ICU), and invasive procedures were factors asso-
ciated with 30-day mortality [5, 7, 9, 10]. Furthermore, C. 
albicans is reported as the most frequent isolate in patients 
with solid tumors followed by C. parapsilosis, C. tropicalis, 
or C. glabrata [3, 4, 6, 9, 11].
Appropriate use of antifungal treatment in patients with 
cancer and candidemia is a life-saving measure [4, 5, 7, 9]. 
Echinocandins are an effective treatment against a range of 
Candida species [12], and the Infectious Diseases Society of 
America guidelines recommend echinocandins for treatment 
of IC/candidemia [13]. Also, guidelines from the European 
Society for Clinical Microbiology and Infectious Diseases 
strongly recommend echinocandins for the initial treatment 
of candidemia in adults [14].
Digital Features for this article can be found at https:// figsh are. 
com/s/ 5e036 327f4 80a03 0a490.
Echinocandins, including anidulafungin, target Candida 
species by inhibiting beta-(1,3)-d-glucan synthase, essen-
tial for the synthesis of fungal cell wall glucan [12]. Anidu-
lafungin is approved in the USA and Europe for the treat-
ment of IC/candidemia [15, 16]. Previous pooled analyses of 
anidulafungin studies have demonstrated effectiveness and 
tolerability in patients with IC/candidemia, intra-abdominal 
candidiasis, neutropenia, and infections caused by C. parap-
silosis and C. krusei [17–19].
To address the relative scarcity of data on the treatment 
of patients with invasive fungal infections and malignan-
cies, and to explore the temporal effect of tumor diagno-
sis on the risk of fungal infection, this post hoc analysis 
investigated whether the efficacy and safety of anidulafungin 
treatment of patients with IC/candidemia and solid tumors 
varied when summarized by past or recent diagnosis of solid 
tumor diagnosis.
2  Patients and Methods
2.1  Study Data
In this post hoc analysis, patient-level data were pooled and 
analyzed from four open-label, non-comparative studies 
of anidulafungin [20–23] and two double-blind, double-
dummy, randomized studies (Pfizer data on file) that evalu-
ated anidulafungin and caspofungin (Online Resource 1); all 
studies had similar protocols and endpoints. Data from all 
the above studies have been included in a previous analysis 
of the efficacy of anidulafungin in patients with IC [18], and 
this analysis followed a similar methodology.
Conduct was in accordance with applicable legal and 
regulatory requirements, the International Conference on 
Harmonization Guidelines for Good Clinical Practice, and 
the Declaration of Helsinki. The Institutional Review Boards 
or Independent Ethics Committees at each investigational 
center approved the studies. All patients provided written 
informed consent.
2.2  Patients
Male or female patients aged ≥ 18 years for the four open-
labeled and the two randomized studies were included in the 
pooled dataset if they had blood culture-confirmed candi-
demia, or IC confirmed by culture positive for Candida spe-
cies isolated from a normally sterile site or a newly placed 
drain, with or without a positive Candida blood culture, 
within 96 h of entry to the study. Patients could be included 
based on microbiologic evidence of Candida infection, such 
as a positive blood (or tissue specimen) culture for yeast, 
provided confirmation of Candida species was obtained 
within 96 h.
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Patients were also required to have one or more clini-
cal signs and symptoms of fungal infection, including fever, 
hypothermia, hypotension, localized signs and symptoms 
of inflammation at a site with Candida infection within 48 
h of commencing treatment, or radiologic findings indica-
tive of IC. Patients were categorized as neutropenic if they 
had a baseline absolute neutrophil count (ANC) of ≤ 500 
cells/mm3 (cells/µL). Patients included in the analysis had 
either a past diagnosis of solid tumors (time of diagnosis 
≥ 6 months prior to study entry) or a recent diagnosis of 
solid tumors (time of diagnosis < 6 months before study 
entry). Solid tumor status was obtained by examining the 
medical histories of patients using the following search crite-
ria: tumor, neopla* (neoplastic, neoplasia, neoplasm), mass, 
cancer, malign* (malignant, malignancy), growth, oncol* 
(oncology, oncological), carcinoma, adenocarcinoma, and 
hepatoma.
The main exclusion criteria were: more than 48 h of sys-
temic antifungal treatment prior to study entry; previous 
treatment failure for current episode of IC or candidemia; 
or a prosthetic device at a suspected site of infection that 
could not be removed prior to or within 24–48 h of the start 
of the study.
2.3  Treatment
Patients received a single IV loading dose of anidulafungin 
200 mg on day 1, followed by 100 mg once daily and, in all 
studies except one [18], could be switched to oral voricona-
zole or fluconazole therapy after ≥ 5 or ≥ 10 days based on 
pre-specified criteria. IV anidulafungin and oral azole (if 
required) were maintained for ≥ 14 days (and up to a maxi-
mum of 42 days) after the last positive Candida culture and 
resolution of symptoms.
2.4  Endpoints
The primary efficacy endpoint of this post hoc analysis was 
global response success (GRS) rate at the end of intrave-
nous therapy (EOIVT) in the modified intent-to-treat (mITT) 
population. This included patients with solid tumors who 
received at least one dose of anidulafungin (the ITT popula-
tion) and had a confirmed diagnosis of candidemia or a posi-
tive culture for Candida species at study commencement or 
within 96 h of study entry. GRS was achieved with clinical 
success, defined as cure or improvement of clinical signs 
and symptoms with no additional systemic or oral antifungal 
therapy, in conjunction with microbiologic success, defined 
as eradication or presumed eradication of baseline Candida 
species.
Secondary endpoints included GRS rate by baseline path-
ogen and site of infection, evaluated at EOIVT and end of 
all therapy (EOT) in the mITT population. Other secondary 
endpoints were all-cause mortality at days 14 and 28, dura-
tion of therapy (IV and IV + oral), and time to switch to 
oral azole therapy. Safety was assessed by the incidence 
and severity of adverse events occurring during or within 
30 days of the last dose of treatment, recorded by system 
organ class and Medical Dictionary for Regulatory Activi-
ties (MedDRA) preferred terms. Safety analyses were based 
on the ITT population.
2.5  Statistical Analysis
All primary and secondary endpoints were summarized by 
the time of diagnosis. The past diagnosis was ≥ 6 months 
since the time of diagnosis, and recent was < 6 months. 
Analyses for baseline demographics and disease character-
istics were for descriptive purposes only. Evaluations were 
primarily descriptive statistics. GRS rates were estimated 
with exact 95% confidence intervals (CI) for binomial pro-
portion (Clopper–Pearson method), and 95% CIs differences 
between past and recent diagnosis groups were estimated 
with exact unconditional limits. Comparisons between past 
and recent diagnosis groups were determined using a Fish-
er’s exact test. Indeterminate or missing data were consid-
ered to be failures.
3  Results
3.1  Patients
Of 539 patients in the cohort pooled from six studies (Online 
Resource 1) [18], 150 had confirmed IC and history of any 
malignancy, and of these, 139 had solid tumors. Among 
patients with solid tumors (Table 1), baseline demograph-
ics and disease characteristics were generally comparable 
between the two diagnostic subgroups. The most frequent 
types of solid tumors were gastrointestinal (60.4%), genitou-
rinary (24.5%), and lung (16.5%). Metastases were present in 
12.9% of all patients in the mITT population. Approximately 
one-half of the patients (52.5%) were male and, overall, the 
mean age (standard deviation [SD]) was 63.1 (13.4) years. 
The majority of patients (90.6%) were aged ≥ 45 years, and 
48.9% were aged ≥ 65 years.
The overall mean (SD) Acute Physiology, Age, Chronic 
Health Evaluation (APACHE) II Score was 14.9 (5.5), and 
most patients (90.9%) were non-neutropenic (Table 1). The 
most frequent baseline pathogens were C. albicans (48.9%) 
and C. glabrata (21.6%). The main sites of infection were 
blood only (75.5%), and other sterile sites (20.1%), followed 
by blood and other sterile sites (4.3%) [data not shown].
Frequent risk factors for IC included the use of broad-
spectrum antibiotics (88.5%), central venous catheters 
(80.3%), and total parenteral nutrition (54.1%) (Table 1). 
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The median (range) duration of IV + oral therapy for the 
mITT population was 15.0 (1–56) days. Fifty-four of 139 
patients (38.8%) in the mITT population switched to oral-
only therapy for a median (range) duration of 9.0 (5–35) 
days, and a median time to switch of 8.0 days (range: 4–34). 
Among these patients, the proportion of patients switching 
to oral azoles was lower in patients with a past diagnosis 
of solid tumors than a recent diagnosis (42.6% vs 57.4%, 
respectively), and the median time to switch was shorter (6 
vs 10 days, respectively).
3.2  Efficacy Endpoints
The GRS rate in the mITT population was 73.4% (102/139) 
at EOIVT (primary endpoint) and 65.5% (91/139) at EOT 
(Fig. 1). GRS rates at EOIVT and EOT in patients with a 
past tumor diagnosis were 75.5% (37/49) and 71.4% (35/49); 
corresponding GRS rates were 72.2% (65/90) and 62.2% 
(56/90), respectively, in those with a recent diagnosis of 
solid tumors (Fig. 1). GRS rates at both EOIVT and EOT 
were not significantly different between those with recent or 
past diagnosis of solid tumors (p > 0.05).
GRS rates at EOIVT and EOT in the overall population 
were 77.9% and 69.1%, respectively, for C. albicans, and 
67.1% and 61.2%, respectively, for non-albicans Candida 
species (Table 2). GRS rate by the site of infection was 
75.2% for blood-only infections at EOIVT and 65.7% at 
EOT (Table 2). For patients with infection in the blood only, 
those with recent solid tumor diagnosis had a significantly 
smaller GRS at EOT, compared with patients with past solid 
tumor diagnoses (p = 0.049).
All-cause mortality in the overall mITT population was 
20/139 (14.4%) at day 14 and 28/139 (20.1%) at day 28. All-
cause mortality rates were not significantly different between 
populations with a recent and past diagnosis of solid tumors 
at day 14 or overall. At day 28, the all-cause mortality rate 
was significantly higher in those with a recent diagnosis of 
solid tumors (25.6%), compared with those with a past diag-
nosis (10.2%) (p = 0.045).
3.3  Safety Endpoints
Incidence and severity of treatment-emergent adverse events 
(TEAEs) are shown in Table 3. A total of 787 TEAEs were 
observed in 123 patients, and the proportion of patients with 
events was similar in those with a recent (88.9%) or past 
diagnosis of solid tumors (87.8%) (data not shown). The 
majority of all-causality TEAEs in the overall population 
were mild or moderate in severity (642/787; 81.6%). The 
most common TEAEs were gastrointestinal, including diar-
rhea (21/139; 15.1%), nausea (13/139; 9.4%), and vomiting 
(13/139; 9.4%); the pattern was similar in the two tumor 
subgroups (data not shown).
4  Discussion
This analysis of patient-level data pooled from six prospec-
tive studies of anidulafungin showed that in patients with 
IC/candidemia and solid tumors, the GRS rate at EOIVT 
(73.4%; primary endpoint) was comparable to the overall 
GRS rate (75.6% at EOIVT) in patients with IC in the reg-
istrational study [24]. The GRS rates were also comparable 
to a randomized, double-blind comparison of caspofungin 
and amphotericin B in 74 patients with IC and active malig-
nancies. In that investigation, response rates in patients with 
solid tumors were 80% and 59% in the two treatment arms, 
respectively [2].
Additionally, in patients with solid tumors, all-cause mor-
tality rate by 6–8 weeks following discontinuation of IV 
treatment was 40% in caspofungin recipients and 21% in 
recipients of amphotericin B [2]. By comparison, the pre-
sent analysis included a higher number of patients with IC/
candidemia and solid tumors, and the all-cause mortality 
rate was 20.1% at day 28.
Non-albicans Candida infection also represents concern 
in daily clinical practice [1]. In our analysis, C. albicans 
was overall the most common isolate, and GRS rates were 
slightly lower in patients with baseline C. albicans and a past 
solid tumor diagnosis compared with a recent diagnosis at 
EOIVT (74% vs 80%), but not at EOT (70% vs 69%). Over-
all, anidulafungin was effective in patients with baseline C. 
albicans and non-albicans Candida infection (78% and 67% 
at EOIVT, respectively). The characteristics of patients in 
our analysis were generally consistent with other studies [4, 
6, 9], including 49% in our mITT population with IC/candi-
demia due to C. albicans, 60% with solid tumors that were 
located in the gastrointestinal tract, and around half (53%) 
having undergone abdominal surgery. In a separate pooled 
analysis of 79 patients with intra-abdominal candidiasis, the 
overall global response rate following anidulafungin treat-
ment was 73.4% at EOIVT [19].
Neutropenia is a more common characteristic of patients 
with hematologic cancer than patients with solid tumors 
[9]. Our population was comparable with this observation 
in that the majority with solid tumors were non-neutropenic 
at baseline (91%).
There is a paucity of studies that have evaluated the time 
of solid tumor diagnosis as a factor that may determine the 
clinical outcome, and in our analysis, the GRS rate was 
comparable at EOIVT regardless of past or recent diagno-
sis of solid tumors. At EOT, the pattern of global response 
rates was comparable. In a retrospective cohort study of 
144 non-neutropenic patients with candidemia, multivari-
ate analysis showed that one of the predictors of non-albi-
cans candidemia was a recent history of solid tumor [25]. 
A prospective, multicenter, surveillance program in Spain, 
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Table 1  Patient baseline demographics and disease characteristics by time of solid tumor diagnosis (mITT, N = 139)
Characteristic Time of solid tumor  diagnosisa Total
Past (≥ 6 m) Recent (< 6 m)
Number (%) of patients 49 (35.3) 90 (64.7) 139 (100)
Sex, n (%) male 26 (53.1) 47 (52.2) 73 (52.5)
Patients in age group, n (%)
 18–44 years 3 (6.1) 10 (11.1) 13 (9.4)
 45–64 years 20 (40.8) 38 (42.2) 58 (41.7)
 ≥ 65 years 26 (53.1) 42 (46.7) 68 (48.9)
Age, mean (SD) years 65.9 (12.5) 61.6 (13.7) 63.1 (13.4)
Race, n (%)
 White 38 (77.6) 56 (62.2) 94 (67.6)
 Black 5 (10.2) 10 (11) 15 (10.8)
 Asian 2 (4.1) 21 (23.3) 23 (16.5)
 Other 4 (8.2)b 3 (3.3) 7 (5.0)
Weight, mean (SD) kg 75.3 (20.1) 68.0 (16.9)c 70.6 (18.3)
Height, mean (SD) cm 168.5 (9.0)d 167.3 (10.4)e 167.7 (9.9)
APACHE II score, mean (SD) 14.4 (5.3) 15.1 (5.7)c 14.9 (5.5)
 n (%) patients with a  scoref
 ≤ 20 42 (85.7) 73 (81.1) 115 (82.7)
 > 20 7 (14.3) 16 (17.8) 23 (16.5)
ANC,g mean (SD)  103/mm3 6.3 (5.0)h 7.2 (5.7)i 6.9 (5.5)
 n (%) patients with
 ≤ 500 cells/mm3 3 (6.1) 5 (5.6) 8 (5.8)
 > 500 cells/mm3 28 (57.1) 52 (57.8) 80 (57.6)
Baseline diagnosis, n (%)
 Systemic Candidaj 48 (98.0) 88 (97.8) 136 (97.8)
 Candidal sepsis 1 (2.0) 1 (1.1) 2 (1.4)
 Empyema – 1 (1.1) 1 (0.7)
Type of solid tumor, n (%)
 Breast 3 (6.1) 7 (7.8) 10 (7.2)
 Gastrointestinal 24 (49.0) 60 (66.7) 84 (60.4)
 Genitourinary 14 (28.6) 20 (22.2) 34 (24.5)
 Head/neck 2 (4.1) 4 (4.4%) 6 (4.3%)
 Lung 6 (12.2) 17 (18.9) 23 (16.5)
 Skin 3 (6.1) 2 (2.2) 5 (3.6)
 Other/missing 12 (24.5) 15 (16.7) 27 (19.4)
Patients with known metastases, n (%)k 5 (10.2) 13 (14.4) 18 (12.9)
Baseline pathogen, n (%)l
 C. albicans 23 (46.9) 45 (50.0) 68 (48.9)
 C. glabrata 14 (28.6) 16 (17.8) 30 (21.6)
 C. parapsilosis 8 (16.3) 12 (13.3) 20 (14.4)
 C. tropicalis 6 (12.2) 16 (17.8) 22 (15.8)
 C. kefyr 2 (4.1) – 2 (1.4)
 C. krusei 2 (4.1) – 2 (1.4)
 C. lusitaniae 1 (2.0) – 1 (0.7)
 C. famata – 2 (2.2) 2 (1.4)
 C. sake – 1 (1.1) 1 (0.7)
 Candida spp. – 1 (1.1) 1 (0.7)
 Other – 4 (4.4) 4 (2.9)
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conducted in part to identify predictors of death in can-
didiasis, found that 7- versus 30-day mortality in patients 
with hematologic malignancies and solid tumors was 
12.8% (93/726) and 30.6% (220/720). When adjusted by 
the primary source of candidemia and severity of infection 
(severe sepsis or septic shock) in the multivariate regres-
sion analysis, appropriate antifungal treatment within the 
first 48 h was the only factor independently associated with 
lower mortality [26]. This highlights the importance of 
early antifungal treatment of candidiasis in patients with 
solid organ tumors.
De-escalation of antifungal treatment has been assessed 
in a study of 190 critically ill patients with suspected IC 
[27]. The approach, which was undertaken in 20% of the 
patients included, was considered to be safe and was associ-
ated with a shorter median duration of antifungal treatment 
compared with no de-escalation (6 vs 13 days). In our study, 
a higher proportion of patients (38.8%) were switched to 
oral therapy, and the median total duration of therapy (IV + 
oral) was similar in past and recent solid tumor diagnostic 
sub-groups (15 vs 14 days, respectively).
Table 1  (continued)
Characteristic Time of solid tumor  diagnosisa Total
Past (≥ 6 m) Recent (< 6 m)
Risk factors for invasive candidiasis, n (%)m
 Use of broad-spectrum antibiotics 43 (91.5) 65 (86.7) 108 (88.5)
 Use of central venous catheter 40 (85.1) 58 (77.3) 98 (80.3)
 Total parenteral nutrition 24 (51.1) 42 (56.0) 66 (54.1)
 Abdominal surgery 27 (57.4) 37 (49.3) 64 (52.5)
 Surgery 23 (48.9) 39 (52.0) 62 (50.8)
 Length of ICU stay ≥ 4 days 17 (36.2) 26 (34.7) 43 (35.2)
 Mechanical ventilation 14 (29.8) 24 (32.0) 38 (31.1)
 Chemotherapy 13 (27.7) 18 (24.0) 31 (25.4)
 Use of systemic steroids/other immunosuppressants 12 (25.5) 19 (25.3) 31 (25.4)
 Renal insufficiency/failure/dialysis 10 (21.3) 15 (20.0) 25 (20.5)
 Neutropenia 3 (6.4) 7 (9.3) 10 (8.2)
 Solid organ transplant 3 (6.4) 0 3 (2.5)
 Other 15 (31.9) 19 (25.3) 34 (27.9)
APACHE Acute Physiology, Age, Chronic Health Evaluation, ANC absolute neutrophil count, ICU intensive care unit, m months
a Past diagnosis of solid tumors, ≥ 6 months prior to study entry; recent diagnosis, < 6 months before study entry
b 2 other, and 2 unspecified
c N = 89
d N = 48
e N = 85
f N = 138
g Number of patients for whom ANC was recorded at baseline
h N = 31
i N = 57
j Systemic Candida included candidiasis, peritoneal candidiasis, fungal peritonitis, blood culture positive, biliary tract infection fungal, fungemia, 
and fungal test positive
k Metastases recorded as ‘Yes/No’ (Yes = known metastases)
l Patients could have more than one Candida species isolated at baseline
m Patients could have more than one risk factor at baseline
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Elderly patients (aged ≥ 65 years) formed almost half 
(48.9%) of the patients in this post hoc analysis, and older 
age is a factor associated with IC/candidemia in patients 
with cancer [9]. In another post hoc analysis of anidu-
lafungin treatment in critically ill patients, a similar pro-
portion (47%) were elderly patients with IC/candidemia, 
and the median duration of IV anidulafungin treatment was 
comparable in elderly and non-elderly patients (14.0 vs 14.5 
days) [28], similar to the present analysis. Overall, switch to 
oral fluconazole or voriconazole occurred in 58/170 (34%) 
of patients in the earlier investigation [28], also similar to 
the proportion in our analysis.
Overall, anidulafungin was well tolerated, and the major-
ity of TEAEs were mild-to-moderate in severity; no new 
safety signals arose from this analysis [24]. The number of 
TEAEs experienced by patients with a past or recent diag-
nosis of solid tumors was generally similar.
One limitation of this analysis was that four studies were 
open-label and conducted at different times. However, all 
studies had a similar design that permitted the pooling 
of data. Our analysis was post hoc and not pre-planned 
by the individual study protocols. Susceptibility testing 
was not evaluated as part of this pooled analysis but has 
been described for a number of the individual prospective 
studies of anidulafungin [20, 22, 23, 28], and in pooled 
populations [17, 18]. Also, due to the limited number 
of patients, no multivariate analysis was performed, and 
patients were included either with solid tumors or a history 
of solid tumors. Selection of the time of past or present 
diagnosis of solid tumors did not lead to the identification 
of a difference between the effect of treatment in the two 
sub-groups, but we cannot exclude the possibility that fur-
ther investigations using this or a different definition and a 
larger group of patients may be needed. Our study did not 
evaluate the potential for drug–drug interactions (DDIs). In 
recent years, several new immunotherapeutic agents have 
been developed for the treatment of patients with hemato-
logic malignancies and solid tumors, and, for some of these 
new agents, the use of azoles that are strong inhibitors of 
cytochrome P450 3A4 is precluded due to the potential 
for DDIs [29]. Anidulafungin does not undergo hepatic 
metabolism, nor does it interact with the cytochrome P450 
enzymes involved in DDIs [30]. No significant interac-
tions between anidulafungin and cyclosporine, tacrolimus, 
rifampin, voriconazole, or liposomal amphotericin B are 
currently known [16].
5  Conclusion
Anidulafungin was effective for the treatment of IC/candi-
demia in patients regardless of past or recent time of solid 
tumor diagnosis. The safety results were consistent with the 
known profile of anidulafungin.
Fig. 1  Anidulafungin global 
response success rates at 
EOIVT and EOT by the time of 
solid tumor diagnosis (mITT, 
N = 139). EOIVT end of 
intravenous treatment; EOT end 
of treatment; m months; ns not 
significant based on Fisher’s 
exact test. Past diagnosis of 
solid tumors, ≥ 6 months prior 
to study entry; recent diagnosis, 
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Table 3  Incidence and severity of treatment-emergent adverse events 
during all treatment (IV anidulafungin + oral azole) by system organ 
class (ITT)
IV intravenous, m months, MedDRA Medical Dictionary for Regula-
tory Activities
a If the same patient in a given treatment had more than one occur-
rence in the same preferred term event category, only the most severe 
occurrence is taken. Patients are counted only once per treatment in 
each row
b MedDRA v19.1
c Includes device breakage, device occlusion
Total
Patients with adverse events, n/N (%) 123/139 (88.5)











Gastrointestinal 64 (46.0) 12
Infections and infestations 62 (44.6) 22
General and administration site conditions 47 (33.8) 14
Respiratory, thoracic and mediastinal 46 (33.1) 18
Metabolism and nutrition 44 (31.7) 3
Psychiatric 33 (23.7) 2
Vascular 31 (22.3) 9
Investigations 29 (20.9) 1
Cardiac 28 (20.1) 9
Blood and lymphatic system 26 (18.7) 7
Renal and urinary tract 20 (14.4) 6
Nervous system 20 (14.4) 3
Skin and subcutaneous tissue 20 (14.4) 2
Neoplasms, benign, malignant and unspecified 15 (10.8) 13
Injury, poisoning and procedural complications 13 (9.4) 3
Musculoskeletal and connective tissue 12 (8.6) 0
Hepatobiliary 11 (7.9) 3
Eye 7 (5.0) 0
Product  issuesc 6 (4.3) 0
Surgical and medical 4 (2.9) 1
Reproductive system and breast 2 (1.4) 1
Immune system 2 (1.4) 0
Ear and labyrinth 2 (1.4) 0
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